tbuckley/cabot-search huggingface dataset:
Nanoparticle Association: In Vivo Quantification of Nanoparticle Association with Immune Cell Subsets in Blood (Adv. Healthcare Mater. 9/2021)
Authors: Yih Rue Ong, Robert De Rose, Angus P. R. Johnston
Journal: Advanced Healthcare Materials (2021)

The clearance of nanoparticles in vivo is mediated by circulating white blood cells. In article number 2002160, Angus P. R. Johnston and co-workers develop an assay that quantifies the in vivo interactions of nanoparticles with different subsets of circulating white blood cells, which shows significant differences to the association observed between nanoparticles and white blood cells ex vivo. The cover image shows an artistic representation of blue nanoparticles binding to white blood cells in a capillary.
Audio Interview: India’s Covid-19 Crisis
Authors: Eric J. Rubin, Lindsey R. Baden, Zarir F. Udwadia, Stephen Morrissey
Journal: New England Journal of Medicine (2021)

India’s Covid-19 Crisis In this audio interview conducted on May 4, 2021, the editors are joined by Mumbai pulmonologist Zarir Udwadia, who assesses the current surge of Covid-19 cases in India, it...
EFFECTIVENESS AND SAFETY OF APIXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ENROLLED IN MEDICARE AND VETERAN AFFAIRS
Authors: Steven Bruce Deitelzweig, Janvi Sah, Amiee Kang, Cristina Russ, Madison Preib, Amol Dhamane, Anna Ratiu, Matthew Cato, Tamuno Alfred, Edi Levi, Manuela Di Fusco
Journal: Journal of the American College of Cardiology (2021)
Andrew Ransford: orthopaedic surgeon who invented the Ransford loop
Authors: Rebecca Wallersteiner
Journal: BMJ (2021)

Andrew Ransford (“Andy”) was born in Kenya to Oliver Ransford, a doctor in the Colonial Service and an acknowledged authority on David Livingstone, and Irene (nee Galloway), formerly a nurse at Westminster Hospital. He grew up in Bulawayo, Zimbabwe, with two younger sisters, one of whom trained as a nurse at St Thomas’ and the other who remained farming in Africa. The family settled in Southern Rhodesia, where Ransford attended Milton Junior School and later Michaelhouse, a boarding school in the Kwazulu-Natal midlands in South Africa, a three day train journey from his family. At school he shone academically and enjoyed playing rugby. Given he came from a medical family it was natural for him to study medicine. At 18, he spent a year at the University of Cape Town to achieve the necessary academic level to enter medical school.

In 1960 he arrived in England to study medicine at Emmanuel College, Cambridge, supported by a scholarship from the Rhodesian government. A gentle giant at 195 cm tall, he played in the first 15 for his university college rugby team. After graduating, he went on to University College London medical school to specialise in surgery and qualified in medicine in 1965. …
IMPACT OF PREOPERATIVE LYMPHOPENIA ON OUTCOMES AFTER HEART TRANSPLANT
Authors: Sneha S. Jain, Kevin J. Clerkin, Zachary B. Roth, Justin A. Fried, Jayant Raikhelkar, Jan M. Griffin, Paolo C. Colombo, Melana Yuzefpolskaya, Farhana Latif, Veli K. Topkara, Maryjane A. Farr, Yoshifumi Naka, Koji Takeda, Gabriel Sayer, Nir Uriel
Journal: Journal of the American College of Cardiology (2021)
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
Authors: Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison
Journal: HemaSphere (2021)

Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAKARTA study in adult patients with intermediate- or high-risk JAK-inhibitor-naïve MF. The effect of fedratinib 400 mg/d on patient-reported MF symptoms and HRQoL in JAKARTA was assessed. Participants completed the modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0), which evaluates 6 key MF symptoms (night sweats, early satiety, pruritus, pain under ribs on the left side, abdominal discomfort, bone/muscle pain). The modified MFSAF v2.0 was completed during the first 6 treatment cycles and at end of cycle 6 (EOC6). Symptom response was a ≥50% improvement from baseline in total symptom score (TSS). Overall HRQoL was assessed by EQ-5D-3L health utility index (HUI) score. The MFSAF-evaluable population comprised 91/96 patients randomized to fedratinib 400 mg and 85/96 patients randomized to placebo. Mean baseline TSS was 17.6 and 14.7 for fedratinib and placebo, respectively, and mean EQ-5D-3L HUI was 0.70 and 0.72. Fedratinib elicited statistically significant and clinically meaningful improvements in TSS from baseline versus placebo at all postbaseline visits. Symptom response rates at EOC6 were 40.4% with fedratinib and 8.6% with placebo (OR 7.0 [95% CI, 2.9-16.9]; P &lt; 0.001), and a significantly higher proportion of fedratinib-treated patients achieved clinically meaningful improvement from baseline on the EQ-5D-3L HUI at EOC6 (23.2% versus 6.5%; P = 0.002). Fedratinib provided clinically meaningful improvements in MF symptoms and overall HRQoL versus placebo in patients with JAK-inhibitor-naïve MF.
Screening for Hypertension in Adults
Authors: Janelle M. Guirguis-Blake, Corinne V. Evans, Elizabeth M. Webber, Erin L. Coppola, Leslie A. Perdue, Meghan Soulsby Weyrich
Journal: JAMA (2021)

<h3>Importance</h3> Hypertension is a major risk factor for cardiovascular disease and can be modified through lifestyle and pharmacological interventions to reduce cardiovascular events and mortality. <h3>Objective</h3> To systematically review the benefits and harms of screening and confirmatory blood pressure measurements in adults, to inform the US Preventive Services Task Force. <h3>Data Sources</h3> MEDLINE, PubMed, Cochrane Collaboration Central Registry of Controlled Trials, and CINAHL; surveillance through March 26, 2021. <h3>Study Selection</h3> Randomized clinical trials (RCTs) and nonrandomized controlled intervention studies for effectiveness of screening; accuracy studies for screening and confirmatory measurements (ambulatory blood pressure monitoring as the reference standard); RCTs and nonrandomized controlled intervention studies and observational studies for harms of screening and confirmation. <h3>Data Extraction and Synthesis</h3> Independent critical appraisal and data abstraction; meta-analyses and qualitative syntheses. <h3>Main Outcomes and Measures</h3> Mortality; cardiovascular events; quality of life; sensitivity, specificity, positive and negative predictive values; harms of screening. <h3>Results</h3> A total of 52 studies (N = 215 534) were identified in this systematic review. One cluster RCT (n = 140 642) of a multicomponent intervention including hypertension screening reported fewer annual cardiovascular-related hospital admissions for cardiovascular disease in the intervention group compared with the control group (difference, 3.02 per 1000 people; rate ratio, 0.91 [95% CI, 0.86-0.97]). Meta-analysis of 15 studies (n = 11 309) of initial office-based blood pressure screening showed a pooled sensitivity of 0.54 (95% CI, 0.37-0.70) and specificity of 0.90 (95% CI, 0.84-0.95), with considerable clinical and statistical heterogeneity. Eighteen studies (n = 57 128) of various confirmatory blood pressure measurement modalities were heterogeneous. Meta-analysis of 8 office-based confirmation studies (n = 53 183) showed a pooled sensitivity of 0.80 (95% CI, 0.68-0.88) and specificity of 0.55 (95% CI, 0.42-0.66). Meta-analysis of 4 home-based confirmation studies (n = 1001) showed a pooled sensitivity of 0.84 (95% CI, 0.76-0.90) and a specificity of 0.60 (95% CI, 0.48-0.71). Thirteen studies (n = 5150) suggested that screening was associated with no decrement in quality of life or psychological distress; evidence on absenteeism was mixed. Ambulatory blood pressure measurement was associated with temporary sleep disturbance and bruising. <h3>Conclusions and Relevance</h3> Screening using office-based blood pressure measurement had major accuracy limitations, including misdiagnosis; however, direct harms of measurement were minimal. Research is needed to determine optimal screening and confirmatory algorithms for clinical practice.
EFFECTS OF NESIRITIDE, SERELAXIN, AND ULARITIDE IN ACUTE HEART FAILURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Jan Mazur, Tam N.M. Ngo, Hoang T. Phan, Khanh Pham, Thai T. Nguyen, Hong M. Vu, Thai Truong, Ngan P. Phuong, Tuan M. Nguyen, Tuyen V. Le, Christopher Rosse, Cassady Palmer, Eugene Chung, Vien Truong
Journal: Journal of the American College of Cardiology (2021)
THE ESSENCE OF SENESCENCE
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biodegradable magnesium pins enhanced the healing of transverse patellar fracture in rabbits
Authors: Dick Ho Kiu Chow, Jiali Wang, Peng Wan, Lizhen Zheng, Michael Tim Yun Ong, Le Huang, Wenxue Tong, Lili Tan, Ke Yang, Ling Qin
Journal: Bioactive Materials (2021)

Displaced fractures of patella often require open reduction surgery and internal fixation to restore the extensor continuity and articular congruity. Fracture fixation with biodegradable magnesium (Mg) pins enhanced fracture healing. We hypothesized that fixation with Mg pins and their degradation over time would enhance healing of patellar fracture radiologically, mechanically, and histologically. Transverse patellar fracture surgery was performed on thirty-two 18-weeks old female New Zealand White Rabbits. The fracture was fixed with a pin made of stainless steel or pure Mg, and a figure-of-eight stainless steel band wire. Samples were harvested at week 8 or 12, and assessed with microCT, tensile testing, microindentation, and histology. Microarchitectural analysis showed that Mg group showed 12% higher in the ratio of bone volume to tissue volume at week 8, and 38.4% higher of bone volume at week 12. Tensile testing showed that the failure load and stiffness of Mg group were 66.9% and 104% higher than the control group at week 8, respectively. At week 12, Mg group was 60.8% higher in ultimate strength than the control group. Microindentation showed that, compared to the Control group, Mg group showed 49.9% higher Vickers hardness and 31% higher elastic modulus at week 8 and 12, respectively. At week 12, the new bone of Mg group remodelled to laminar bone, but those of the control group remained woven bone-like. Fixation of transverse patellar fracture with Mg pins and its degradation enhanced new bone formation and mechanical properties of the repaired patella compared to the Control group.
ONLY THE Z-AXIS COMPONENT OF QRS 3D VOLTAGE TIME INTEGRAL (3D QRS AREA) IS PREDICTIVE OF CARDIAC RESYNCHRONIZATION THERAPY BENEFIT
Authors: Tucker Morey, Christopher J. Harvey, Uzair Mahmood, Nikhil Parimi, Sean Lacy, Ashley DeBauge, Seth Sheldon, Madhu Reddy, Amit Noheria
Journal: Journal of the American College of Cardiology (2021)
Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma
Authors: Hanyu Rao, Xiaoxue Li, Min Liu, Jing Liu, Wenxin Feng, Huayuan Tang, Jin Xu, Wei-Qiang Gao, Li Li
Journal: Cancer Research (2021)

Abstract Patients with polycystic kidney disease (PKD) are at a high risk of developing renal cell carcinoma (RCC). However, little is known about genetic alterations or changes in signaling pathways during the transition from PKD to RCC. SET domain–containing 2 (SETD2) is a histone methyltransferase, which catalyzes tri-methylation of H3K36 (H3K36me3) and has been identified as a tumor suppressor in clear cell renal cell carcinoma (ccRCC), but the underlying mechanism remains largely unexplored. Here we report that knockout of SETD2 in a c-MYC–driven PKD mouse model drove the transition to ccRCC. SETD2 inhibited β-catenin activity at transcriptional and posttranscriptional levels by competing with β-catenin for binding promoters of target genes and maintaining transcript levels of members of the β-catenin destruction complex. Thus, SETD2 deficiency enhanced the epithelial-to-mesenchymal transition and tumorigenesis through the hyperactivation of Wnt/β-catenin signaling. Our findings reveal previously unrecognized roles of SETD2-mediated competitive DNA binding and H3K36me3 modification in regulating Wnt/β-catenin signaling during the transition from PKD to ccRCC. The novel autochthonous mouse models of PKD and ccRCC will be useful for preclinical research into disease progression. Significance: These findings characterize multiple mechanisms by which SETD2 inhibits β-catenin activity during the transition of polycystic kidney disease to renal cell carcinoma, providing a potential therapeutic strategy for high-risk patients.
Management of Crohn Disease—Reply
Authors: Kelly Cushing, Peter D. R. Higgins
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UTILIZATION OF TECHNETIUM-99M PYROPHOSPHATE IMAGING FOR THE DIAGNOSIS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): A MULTI-CENTER, COMMUNITY HOSPITAL-BASED STUDY
Authors: Rabah Alreshq, Steven Sigman, Catherine N. Marti, Andrew Darlington, Arun Krishnamoorthy, Benjamin Demoss, Frederick Ruberg
Journal: Journal of the American College of Cardiology (2021)
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial
Authors: Daniel Freeman, Bao Sheng Loe, Ly-Mee Yu, Jason Freeman, Andrew Chadwick, Cristian Vaccari, Milensu Shanyinde, Victoria Harris, Felicity Waite, Laina Rosebrock, Ariane Petit, Samantha Vanderslott, Stephan Lewandowsky, Michael Larkin, Stefania Innocenti, Andrew J Pollard, Helen McShane, Sinéad Lambe
Journal: The Lancet Public Health (2021)
INTRAOPERATIVE MORTALITY AND DISPOSITION OF ELECTIVE PCI: INSIGHTS FROM THE NATIONAL AMBULATORY SURGERY SAMPLE
Authors: Ioannis Milioglou, Fouad Chouairi, Paul Miller, Tariq Ahmad, Samuel Reinhardt, Bradley Kay, Katherine Clark, Aidan Milner, Justin Pacor, Cesar Caraballo, Neal Ravindra, Daniel Friedman, Nihar Desai, Avirup Guha
Journal: Journal of the American College of Cardiology (2021)
Abstract 17374: Trends in Prevalence and Percutaneous Coronary Intervention Utilization Among Patients With Anomalous Coronary Artery
Authors: Byomesh Tripathi, Shilpkumar Arora, Varun Kumar, Varunsiri Atti, Nikhil Nalluri, Purnima Sharma, Shikha Malhotra, Nileshkumar J Patel
Journal: Circulation (2018)

Introduction: Previous studies on anomalous coronary artery suggested its association with significant stenosis and worse in-hospital outcomes. Limited information is available about the prevalence of anomalous coronary artery and utilization of Percutaneous coronary intervention(PCI) in this population. Methods: We derived our study cohort from HCUP’s Nationwide Inpatient Sample (NIS) database (2004-2014). Anomalous coronary artery and PCI related hospitalizations were recognized using ICD-9-CM diagnostic code 746.85 and procedural code 36.06,36.07 and 00.66 respectively in either primary or secondary fields, Cochran-Armitage trend test was used to generate p-value. Results: We identified 59,819 patients with anomalous coronary artery in our study cohort (83.6% age ≥50 years, 69.5% male, 65.2% white), exhibiting significant increase from 4,187 in 2004 to 5940 in 2014 (relative increase of 45.3 %). Utilization of PCI in this population has increased from 14% in 2004 to 17.3 % in 2014 (ptrend &lt;.0001). The most common comorbid conditions coexisting with PCI admissions were dyslipidemia (68.5%), Hypertension (66%), Coronary artery disease (54.2%) and Smoking (41.3%), STEMI (27.3%); All exhibit increasing prevalence from 2004-2014 (ptrend &lt;.0001). (Fig 1B). Weekend admission has increased from 16.2 % to 23% (ptrend &lt;.0001) and maximum PCI (40.6%) were performed in the southern region of United States. Conclusions: Prevalence of anomalous coronary artery has significantly increased in united states with a concomitant increase in PCI utilization in this population. We also noted a concurrent increase in the prevalence of comorbidities such as smoking, dyslipidemia, coronary artery disease, hypertension, STEMI and weekend admission over the study period in these patients.
BACK TO THE BASICS: RIGHT VENTRICULAR LONGITUDINAL DIMENSION AND MID RIGHT AND LEFT VENTRICULAR RATIO AS PROGNOSTIC AND DIAGNOSTIC TOOLS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
Authors: Juan A. Quintero-Martinez, Waldemar E. Wysokinski, Sandra N. Cordova, Md Mashiul Alam, Jain Vaibhav, Danielle T. Vlazny, Damon E. Houghton, Ana Casanegra, Hector Villarraga
Journal: Journal of the American College of Cardiology (2021)
Sex and age differences in the incidence of acute myocardial infarction during the COVID-19 pandemic in a Swedish health-care region without lockdown: a retrospective cohort study
Authors: Jenny Huynh, Neshro Barmano, Jan-Erik Karlsson, Andreas Stomby
Journal: The Lancet Healthy Longevity (2021)

BackgroundThe incidence of acute myocardial infarction has decreased during the COVID-19 pandemic, but sex and age differences in this change in incidence have not been tested. Thus, we aimed to compare the incidence of acute myocardial infarction in a health-care region in Sweden during the COVID-19 pandemic with previous years and to evaluate sex and age differences.MethodsWe did a retrospective, observational cohort study using data from a national registry of patients admitted to coronary care units in Sweden. All patients admitted to one of three hospitals in Region Jönköping County with a diagnosis of acute myocardial infarction during the COVID-19 pandemic (March 1 to July 31, 2020) or reference period (March 1 to July 31, 2017–19) were included. The incidence of acute myocardial infarction (ST-elevation and non-ST-elevation) was calculated for both study periods. Participants were grouped according to sex and age (<70 years vs ≥70 years). The incidence and the incidence rate ratio (IRR) between the two study periods was calculated for each group and compared between groups using the Breslow-Day test.FindingsThe study included 1088 participants, 846 who were admitted for acute myocardial infarction during the reference period and 242 who were admitted during the COVID-19 pandemic period. The IRR of acute myocardial infarction for the COVID-19 period compared with the reference period was 0·85 (95% CI 0·73–0·98). The IRR for acute myocardial infarction was significantly lower among women aged 70 years or older (0·56 [0·40–0·78]) than among men aged 70 years or older (0·97 [0·77–1·23]; p=0·0074).InterpretationThe incidence of acute myocardial infarction decreased predominantly among women aged 70 years or older during the COVID-19 pandemic. This highlights potential sex differences in health effects of the COVID-19 pandemic, which should be further elucidated.FundingNone.
ONE-YEAR CLINICAL OUTCOMES OF DIRECT IMPLANTATION OF A SUPRA-ANNULAR SELF-EXPANDING VALVE
Authors: Georgios Benetos, Maria Karmpalioti, Maria Drakopoulou, Konstantinos Stathogiannis, Maria Xanthopoulou, George Latsios, Andreas Synetos, Evangelia Bei, Vassilis Voudris, Elias Kosmas, Georgios Katsimagklis, Vicki Zeniou, Haim Danenberg, Manolis Vavuranakis, Dimitris Tousoulis, Konstantinos Tsioufis, Konstantinos Toutouzas
Journal: Journal of the American College of Cardiology (2021)
循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告)冠攣縮性狭心症の診断と治療に関するガイドライン
Authors: Ogawa Hisao, Akasaka Takashi, Okumura Ken, Kawashima Seinosuke, Kawasuji Michio, Kimura Kazuo, Saito Satoshi, Shimokawa Hiroaki, Sueda Shozo, Takeyama Yoichi, Tanabe Yasuhiko, Dobashi Kazufumi, Node Koichi, Hattori Ryuichi, Mizuno Kyoichi, Miwa Kunihisa, Murohara Toyoaki, Mori Masahiro, Yamagishi Masakazu, Yoshimura Michihiro, Inoue Akio, Yukibuki Norio, Oshita Akira, Umikita Koichi, Kono Hiroaki, Kojima Atsushi, Kosuge Masami, Soejima Hirofumi, Saida Shigeho, Nakayama Masafumi, Yasuda Satoshi, Kishida Hiroshi, Tomoike Yoshinobu, Haji Kazuo, Yokoyama Mitsuhiro
Journal: Circulation (2008)
CARDIAC REHABILITATION IMPROVES FUNCTIONAL CAPACITY IN PATIENTS WITH ADULT CONGENITAL HEART DISEASE
Authors: Siyuan Sheng, Jodi Feinberg, John Bostrom, Ying Tang, Greg Sweeney, Alicia Pierre, Edward Katz, Jonathan Whiteson, Francois Haas, John Dodson, Dan Halpern
Journal: Journal of the American College of Cardiology (2021)
IMPELLA MECHANICAL SUPPORT FOR CARDIOGENIC SHOCK FROM TAKOTSUBO STRESS CARDIOMYOPATHY IN A PATIENT WITH PREEXISTING HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
Authors: Suraj K. Mishra, Raj Dalsania, Joseph Noto, Martin Keane
Journal: Journal of the American College of Cardiology (2021)
PERCUTANEOUS ENDOVASCULAR TREATMENT FOR REPAIR OF LATE POSTSURGICAL COMPLICATIONS IN UNIVENTRICULAR PHYSIOLOGY
Authors: Imelda Rincon, Lucelli Yañez-Gutierrez, Horacio Marquez-Gonzalez, David Salazar-Lizarraga, Cristopher German-Arroyo, Israel Garcia-Davalos, Diana Lopez-Gallegos
Journal: Journal of the American College of Cardiology (2021)
DAYS ALIVE OUT OF HOSPITAL WITH INITIAL INVASIVE VS CONSERVATIVE MANAGEMENT IN THE ISCHEMIA TRIAL
Authors: Harvey White, Sean O'Brien, Karen Alexander, Sripal Bangalore, Jiang Hao Li, Cholenahally Manjunath, Jose Lopez-Sendon, Jesus Peteiro, Gilbert Gosselin, Jeffrey Berger, Aldo Pietro Maggioni, William Boden, Harmony Reynolds, Judith Hochman, David Maron
Journal: Journal of the American College of Cardiology (2021)